Addressing residual risk issues at anthrax cleanups: how clean is safe?
- PMID: 16020189
- DOI: 10.1080/15287390590912621
Addressing residual risk issues at anthrax cleanups: how clean is safe?
Abstract
Since the 2001 attacks in which Bacillus anthracisspores were mailed to various media offices and two U.S. Senators, considerable interest has focused on developing estimates of the risk of contracting inhalational anthrax from exposure to such spores. Credible risk estimates would have significant utility in establishing future cleanup goals for contaminated sites. To perform a meaningful risk assessment, one needs sufficient data to identify the hazards, conduct dose-response assessment, and assess exposure. This report reviews the existing data on mortality produced by Bacillus anthracisspores in laboratory animals and humans. In particular, it focuses on the 11 cases of inhalational anthrax resulting from the 2001 attacks and their impact on hazard identification activities. It also addresses factors that may contribute to increased risk among exposed populations and the sources of uncertainty in dose response analysis. The article examines the state of the science for assessing exposure levels to Bacillus anthracis spores and concludes that significant challenges exist to performing robust assessments of risk. This conclusion supports the policy position of the U.S. Environmental Protection Agency (EPA) that there should be no growth of Bacillus anthracis spores from all postremediation environmental samples, for the cleanup of a site to be judged effective and for that site to be considered safe for reoccupancy. This has been the ultimate criterion for efficacy of cleanups performed in response to the 2001 anthrax attacks.
Similar articles
-
Efficacy and durability of Bacillus anthracis bacteriophages used against spores.J Environ Health. 2003 Jul-Aug;66(1):9-15, 24; quiz 27-8. J Environ Health. 2003. PMID: 12879575
-
Setting risk-informed environmental standards for Bacillus anthracis spores.Risk Anal. 2010 Oct;30(10):1602-22. doi: 10.1111/j.1539-6924.2010.01443.x. Risk Anal. 2010. PMID: 20626695
-
No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001.Clin Infect Dis. 2005 Oct 1;41(7):991-7. doi: 10.1086/432937. Epub 2005 Aug 29. Clin Infect Dis. 2005. PMID: 16142664
-
[Inhalation anthrax].Ugeskr Laeger. 2000 Sep 4;162(36):4786-9. Ugeskr Laeger. 2000. PMID: 10994373 Review. Danish.
-
Benchmark dose analysis for Bacillus anthracis inhalation exposures in the nonhuman primate.Risk Anal. 2012 Oct;32(10):1750-68. doi: 10.1111/j.1539-6924.2012.01808.x. Epub 2012 Apr 1. Risk Anal. 2012. PMID: 22469218 Review.
Cited by
-
Evaluating the long-term persistence of Bacillus spores on common surfaces.Microb Biotechnol. 2018 Nov;11(6):1048-1059. doi: 10.1111/1751-7915.13267. Epub 2018 May 3. Microb Biotechnol. 2018. PMID: 29726106 Free PMC article.
-
Deterministic models of inhalational anthrax in New Zealand white rabbits.Biosecur Bioterror. 2014 Jan-Feb;12(1):29-41. doi: 10.1089/bsp.2013.0067. Epub 2014 Feb 14. Biosecur Bioterror. 2014. PMID: 24527843 Free PMC article.
-
Comparative evaluation of vacuum-based surface sampling methods for collection of Bacillus spores.J Microbiol Methods. 2013 Dec;95(3):389-96. doi: 10.1016/j.mimet.2013.10.015. Epub 2013 Oct 29. J Microbiol Methods. 2013. PMID: 24184017 Free PMC article.
-
Physiological Responses to a Single Low-Dose of Bacillus anthracis Spores in the Rabbit Model of Inhalational Anthrax.Pathogens. 2020 Jun 11;9(6):461. doi: 10.3390/pathogens9060461. Pathogens. 2020. PMID: 32545184 Free PMC article.
-
Suitability of Commercial Transport Media for Biological Pathogens under Nonideal Conditions.Int J Microbiol. 2011;2011:463096. doi: 10.1155/2011/463096. Epub 2011 Oct 30. Int J Microbiol. 2011. PMID: 22121364 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials